Friday, May 24, 2024

Surge in Health Concerns Linked to Ozempic, Risks Escalate by Up to 900%, Expert Warns

Renowned medical expert, Dr. Mark Hyman, has raised alarms over the diabetes medication Ozempic, which is increasingly used off-label for weight loss. Despite its effectiveness, Hyman warns that the drug could heighten certain health risks dramatically, with some increasing by as much as 900%.

Ozempic, a medication originally designed to manage type 2 diabetes, has gained traction for its notable weight loss results. However, its rising popularity comes with growing concerns about severe side effects, ranging from moderate to severe, which have forced numerous patients to discontinue its use permanently. Dr. Mark Hyman, co-founder and chief medical officer at Function, voiced his concerns during a recent episode of “The Diary Of A CEO” podcast, highlighting the drug’s potential to significantly escalate specific health risks.

Approved in 2017 as a glucagon-like peptide-1 receptor agonist (GLP-1RA), Ozempic has not been on the market long enough for long-term effects to be fully understood. Dr. Hyman criticized the drug for not fostering sustainable lifestyle changes, describing it as a “pharmacological straight jacket” that might seem necessary for severely overweight individuals avoiding more invasive treatments like gastric bypass.

Moreover, Dr. Hyman expressed apprehension about Ozempic’s impact on muscle loss, which can adversely affect metabolism and overall health. He also pointed out an alarming increase in severe side effects, including a 450% rise in the risk of bowel obstructions—conditions serious enough to require surgical intervention. The U.S. Food and Drug Administration (FDA) took action in September 2023 by updating Ozempic’s label to include warnings about ileus, a type of bowel obstruction.

The risks associated with Ozempic extend further, with Dr. Hyman highlighting a staggering 900% increase in the risk of pancreatitis, a potentially fatal condition that inflames the pancreas and disrupts digestive functions. He attributed these side effects directly to the drug’s mechanisms, which affect gut hormones and metabolic functions, leading to these significant health concerns.

In light of these discussions, a spokesperson from Novo Nordisk, the manufacturer of Ozempic, assured that patient safety remains their paramount concern. They emphasized their commitment to continual collaboration with the FDA to monitor the safety profile of their GLP-1RA medications, asserting confidence in their drugs’ safety and efficacy when used correctly under professional guidance.

Dr. Hyman concluded by advocating for a broader approach to tackling obesity, emphasizing the need for significant societal changes, including policy shifts and education, to address the root causes of obesity rather than relying solely on pharmacological solutions.

Related Articles

Latest Articles

Most Popular